World Journal of Surgery

, Volume 30, Issue 5, pp 787–793

Does Familial Non-Medullary Thyroid Cancer Adversely Affect Survival?

  • Frederic Triponez
  • Mariwil Wong
  • Cord Sturgeon
  • Nadine Caron
  • David G. Ginzinger
  • Mark R. Segal
  • Electron Kebebew
  • Quan-Yang Duh
  • Orlo H. Clark
Article

DOI: 10.1007/s00268-005-0398-x

Cite this article as:
Triponez, F., Wong, M., Sturgeon, C. et al. World J. Surg. (2006) 30: 787. doi:10.1007/s00268-005-0398-x
  • 132 Views

Abstract

Background

Familial non-medullary thyroid cancer (FNMTC) is associated with a higher rate of multifocality and a higher recurrence rate than sporadic thyroid cancer. However, the effect of FNMTC on life expectancy is unknown.

Material and Methods

Using data from our FNMTC database, we calculated life expectancy and survival rates after diagnosis of FNMTC and compared the results with the rates for unaffected family members and for the standard US population. Overall life expectancy and survival rates were calculated using the Kaplan–Meier method. We compared patients from families with 2 affected members with patients from families with ≥3 affected members. We also compared patients diagnosed in a known familial setting (index cases and subsequent cases) with patients diagnosed before the familial setting was recognized.

Results

There were 139 affected patients with 757 unaffected family members. The mean age at diagnosis was 40.8 ± 13.9 years and the mean follow-up time was 9.4 ± 11.7 years. Ten patients died of thyroid cancer during follow-up. The life expectancy of patients with FNMTC was similar to that of their unaffected family members. Survival was significantly shorter for patients with 3 or more affected family members, for patients diagnosed before the familial setting was recognized, and for patients with anaplastic cancer.

Conclusions

Our results suggest that FNMTC may be more aggressive than sporadic thyroid cancer, particularly in families with 3 or more affected members. However, when recognized and treated appropriately, it does not significantly shorten the overall life expectancy of the affected patients.

Copyright information

© Société Internationale de Chirurgie 2006

Authors and Affiliations

  • Frederic Triponez
    • 2
    • 4
  • Mariwil Wong
    • 1
  • Cord Sturgeon
    • 1
  • Nadine Caron
    • 1
  • David G. Ginzinger
    • 2
  • Mark R. Segal
    • 3
  • Electron Kebebew
    • 1
  • Quan-Yang Duh
    • 1
  • Orlo H. Clark
    • 1
  1. 1.Endocrine Surgical OncologyUCSF / Mount Zion Medical CenterSan FranciscoUSA
  2. 2.Advanced Research Technologies, Applied BiosystemsFoster CityUSA
  3. 3.Epidemiology and BiostatisticsUCSFSan FranciscoUSA
  4. 4.Thoracic and Endocrine SurgeryUniversity Hospital of GenevaGeneva 14Switzerland